SciBase Collaborates to Enhance Early Detection of Atopic Dermatitis in Infants
SciBase Holding AB (STO: SCIB), a pioneering developer of augmented intelligence solutions for skin disorders, has embarked on an exciting journey to collaborate with the SKIN Research Group at the Vrije Universiteit Brussel. This innovative partnership is aimed at advancing the early detection and prediction of atopic dermatitis— a common type of eczema— and other co-occurring atopic conditions such as asthma and hay fever in infants.
Utilizing Cutting-Edge Technology for Better Health Outcomes
The collaboration will leverage Electrical Impedance Spectroscopy (EIS) technology, a breakthrough method designed to unlock insights that can predict an infant's risk of developing atopic dermatitis. By collecting valuable data from infants, the goal is to create a robust product that could lead to significantly improved healthcare outcomes for children globally. The initiative, expected to span over two years, will involve the enrollment of hundreds of newborns from the DIANA birth cohort.
Expert Insights on Disease Prevention
Assistant professor of the SKIN Research Group, Inge Kortekaas Krohn, expressed optimism regarding the collaboration's potential impact. "Early detection of children at risk of developing atopic dermatitis can lead to timely preventive measures that reduce the burden of disease and its progression to other atopic conditions such as food allergies and allergic asthma. This partnership may significantly enhance the accuracy of prediction, prevention, and overall prognosis for children at risk for eczema and other allergic diseases," he stated.
Looking Forward to a Healthier Future
CEO Pia Renaudin shared her enthusiasm about the collaboration: "This study represents a significant opportunity to make a positive difference in the lives of children and their families, enabling a healthier start in life. At SciBase, we are committed to enhancing disease prediction and prevention, and this partnership aligns perfectly with our mission. The outcomes from this collaboration, alongside our current partnership with Kenvue, reflect our dedication to improving health outcomes for the next generation."
About SciBase and Its Mission
SciBase is a leading global medical technology company specializing in the early detection and prevention of skin disorders. With the development of Nevisense, a unique platform that integrates artificial intelligence and advanced EIS technology, SciBase seeks to enhance diagnostic performance and facilitate proactive skin health management. The company's unwavering commitment is to minimize patient suffering, enabling healthcare professionals to save lives through timely interventions while also reducing healthcare costs.
Foundation Built on Decades of Research
Founded on over 20 years of pioneering research at the Karolinska Institute in Stockholm, Sweden, SciBase continues to be at the forefront of dermatological advancements. The company is dedicated to improving health outcomes and patient experiences through innovative technology.
Frequently Asked Questions
What is the aim of the collaboration between SciBase and SKIN Research Group?
The collaboration aims to predict and prevent atopic dermatitis and related atopic conditions in infants using advanced Electrical Impedance Spectroscopy technology.
How many infants will be involved in the initial study?
Hundreds of newborns will be enrolled from the DIANA birth cohort for a duration of two years in the study.
What technology is SciBase utilizing for this project?
SciBase is utilizing Electrical Impedance Spectroscopy (EIS) technology to gather data and predict the risk of developing atopic dermatitis in infants.
What other conditions are linked to atopic dermatitis in this study?
In addition to atopic dermatitis, the study also focuses on other atopic conditions such as asthma and hay fever.
What is the primary mission of SciBase?
SciBase's mission is to advance disease prediction and prevention in dermatology while improving patient outcomes through innovative technology.
